Company Filing History:

13 out of 2,198

Smithkline Beecham Corporation

patents

5 out of 35

Lubrizol Genetics, Inc.

patents

3 out of 676

Human Genome Sciences, Inc.

Mycogen Plant Science, Inc.

patents

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1989-2011

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 7982005 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders (2011-07-19),

2. 7399837 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders (2008-07-15),

3. 7138498 - Antibodies to MCP-4 (2006-11-21),

4. 6946130 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders (2005-09-20),

5. 6936688 - Human chemokine beta-10 mutant polypeptides (2005-08-30),

6. 6673344 - Antibodies to human CK&bgr;-10/MCP-4 (2004-01-06),

7. 6391589 - Human chemokine beta-10 mutant polypeptides (2002-05-21),

8. 6153441 - Methods of screening for agonists and antagonists for human CCR7 (2000-11-28),

9. 6129913 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated (2000-10-10),

10. 5851525 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated (1998-12-22),

11. 5783184 - Method for treatment and diagnosis of IL-5 mediated disorders (1998-07-21),

12. 5693323 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated (1997-12-02),

13. 5683892 - DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 (1997-11-04),

14. 5432079 - Method for selecting mutants of legume-nodulating bacteria enhanced in (1995-07-11),

15. 5229113 - Bradyrhizobium japonicum nodulation inducing factor (1993-07-20),

Title: Edward Robert Appelbaum: Innovator in IL-5 Therapy

Introduction: Edward Robert Appelbaum, based in Blue Bell, PA, has established himself as a prominent inventor with a focus on therapeutic innovations targeting IL-5 mediated disorders. With a substantial portfolio of 19 patents, Appelbaum's work has made significant contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Among his notable contributions are his latest patents that revolve around recombinant IL-5 antagonists. These innovations include chimeric and humanized IL-5 monoclonal antibodies (mAbs), which are derived from high affinity neutralizing mAbs. The patents focus on pharmaceutical compositions for these mAbs, alongside methods for treatment and diagnostics that can revolutionize the management of IL-5 mediated disorders.

Career Highlights: Edward Robert Appelbaum's career boasts experience at leading companies, including SmithKline Beecham Corporation and Lubrizol Genetics, Inc. His work in these organizations has fostered advancements in medical science, particularly in the domain of immunotherapy.

Collaborations: Throughout his career, Appelbaum has collaborated with accomplished professionals, including Richard M. Cook and Robert S. Ames. Their collective efforts highlight the importance of teamwork in scientific innovation and development, fostering projects that have the potential to improve patient care.

Conclusion: Edward Robert Appelbaum exemplifies the spirit of innovation in biotechnology through his extensive patent portfolio and collaborative projects. His focus on IL-5 antagonists is paving the way for new therapeutic approaches, underscoring the vital role of inventors in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.